Revvity, Inc. (RVTY)
Market Cap | 13.02B |
Revenue (ttm) | 2.75B |
Net Income (ttm) | 693.09M |
Shares Out | 123.53M |
EPS (ttm) | 5.55 |
PE Ratio | 19.07 |
Forward PE | 22.32 |
Dividend | $0.28 (0.27%) |
Ex-Dividend Date | Apr 18, 2024 |
Volume | 617,542 |
Open | 105.54 |
Previous Close | 105.41 |
Day's Range | 104.85 - 106.07 |
52-Week Range | 79.50 - 139.04 |
Beta | 1.10 |
Analysts | Buy |
Price Target | 118.91 (+13.25%) |
Earnings Date | May 9, 2024 |
About RVTY
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its pro... [Read more]
Financial Performance
In 2023, Revvity's revenue was $2.75 billion, a decrease of -16.95% compared to the previous year's $3.31 billion. Earnings were $693.09 million, an increase of 21.77%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price forecast is $118.91, which is an increase of 13.25% from the latest price.
News
Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that it has filed a complaint against Cloud Software Group (CSG) in Massachusetts Superior Court and requested injunctive r...
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals Software, is introducing the new Signals ChemDraw® offering, th...
Revvity Introduces New Workflow to Accelerate Newborn Sequencing Research
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagen...
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced it will present at the following investor conferences in February and March 2024: Citi's 2024 Unplugged MedTech and Life Sci...
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals, is unveiling the Signals ClinicalTM solution, a software-as-a-...
Propelling Diagnostics and Life Sciences Innovation from Early Phase Research to the Clinic: Revvity Showcases Cutting-Edge Solutions at SLAS2024
WALTHAM, Mass.--(BUSINESS WIRE)-- #biotech--Revvity, Inc. is set to boldly unveil its new branding while showcasing more than 40 products from its life sciences and diagnostics portfolio at SLAS2024 t...
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 The Company reported GAA...
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 1...
Revvity Elects Sophie Vandebroek and Michael Klobuchar to its Board of Directors
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that Sophie Vandebroek and Michael Klobuchar have been elected to its board of directors, effective February 1, 2024. “I am...
Revvity to Hold Earnings Call on Thursday, February 1, 2024; Provides Update on Financial Performance
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced that it will release its fourth quarter and full year 2023 financial results prior to market open on Thursday, February 1, 2...
Revvity to Present at J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 42nd annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 10:30 a.m. PT in San Francisco, CA. Preside...
PerkinElmer Acquires Covaris to Create an Innovation-Led, Global Life-Sciences and Diagnostics Platform
SHELTON, Conn.--(BUSINESS WIRE)--PerkinElmer, a leading global analytical services and solutions provider, today announced that it has acquired Covaris, a leading developer of solutions to empower lif...
Revvity Launches EONIS Q System Enabling Faster, Simplified Newborn Screening for SMA and SCID
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc., announced the launch of its EONIS™ Q system, a CE-IVD declared platform enabling laboratories in countries that accept the CE marking to adopt mo...
Revvity to Present at Annual Evercore ISI HealthCONx Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 9:10 a.m. ET in Miami, FL. President and ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. - RVTY
NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revvity, Inc. ("Revvity" or the "Company") (NYSE: RVTY). Such investors are advised to contact ...
Revvity Stock Tumbles 18% as Demand From Pharma and Biotech Customers Falls
Revvity posts third-quarter earnings of $1.18 a share, 1 cent below estimates. Revenue of $670.7 million also came in below forecasts.
Revvity's stock tumbles to lead the S&P 500 losers after earnings miss, lowered outlook
Shares of Revvity Inc. RVTY, -1.09% tumbled 14.2% toward a 3 1/2-year low Monday, enough to pace the S&P 500's SPX, +0.72% premarket decliners, after the health sciences company missed third-quarter e...
Revvity cuts annual forecast on weak demand for diagnostics, contract research
Revvity Inc cut its full-year sales and revenue forecasts after missing Wall Street estimates for third-quarter results, hurt by weak demand for its supplies to life science researchers and diagnostic...
Revvity Announces Financial Results for the Third Quarter of 2023
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended October 1, 2023. The Company reported GAAP earnings per share of $0.08, as com...
Revvity Debuts Inaugural ESG Report
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today unveils its inaugural 2023 Environmental, Social and Governance (ESG) Report. An in-depth overview of the Company's ESG strategy, init...
Revvity and Element Biosciences Announce Collaboration to Improve Next Generation Sequencing Research Workflow
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. and Element Biosciences, Inc., a developer of the AVITI™ System, an innovative and emerging genomic sequencing platform, today announced a co...
Revvity To Hold Earnings Call on Monday, October 30, 2023
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2023 financial results prior to market open on Monday, October 30, 2023. The Company...
Revvity Expands Access to Base Editing Technology With Aim to Accelerate Discovery to Cure
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., (NYSE: RVTY) today unveils its groundbreaking Pin-point™ base editing platform reagents, providing researchers with unparalleled access to implement the...
Revvity Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries.
Revvity to Present at Upcoming September Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced it will present at the 2023 Wells Fargo Healthcare Conference, the Baird 2023 Global Healthcare Conference and the Bank of A...